1
|
Willard FS, Wainscott DB, Showalter AD, Stutsman C, Ma W, Cardona GR, Zink RW, Corkins CM, Chen Q, Yumibe N, Agejas J, Cumming GR, Minguez JM, Jiménez A, Mateo AI, Castaño AM, Briere DA, Sloop KW, Bueno AB. Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor. J Med Chem 2021; 64:3439-3448. [PMID: 33721487 DOI: 10.1021/acs.jmedchem.1c00029] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The identification of LSN3318839, a positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R), is described. LSN3318839 increases the potency and efficacy of the weak metabolite GLP-1(9-36)NH2 to become a full agonist at the GLP-1R and modestly potentiates the activity of the highly potent full-length ligand, GLP-1(7-36)NH2. LSN3318839 preferentially enhances G protein-coupled signaling by the GLP-1R over β-arrestin recruitment. Ex vivo experiments show that the combination of GLP-1(9-36)NH2 and LSN3318839 produces glucose-dependent insulin secretion similar to that of GLP-1(7-36)NH2. Under nutrient-stimulated conditions that release GLP-1, LSN3318839 demonstrates robust glucose lowering in animal models alone or in treatment combination with sitagliptin. From a therapeutic perspective, the biological properties of LSN3318839 support the concept that GLP-1R potentiation is sufficient for reducing hyperglycemia.
Collapse
Affiliation(s)
- Francis S Willard
- Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - David B Wainscott
- Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - Aaron D Showalter
- Diabetes and Complications, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - Cynthia Stutsman
- Diabetes and Complications, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - Wenzhen Ma
- Diabetes and Complications, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - Guemalli R Cardona
- Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - Richard W Zink
- Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - Christopher M Corkins
- Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - Qi Chen
- Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - Nathan Yumibe
- Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - Javier Agejas
- Discovery Chemistry Research and Technologies, Lilly, S.A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Graham R Cumming
- Discovery Chemistry Research and Technologies, Lilly, S.A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - José Miguel Minguez
- Discovery Chemistry Research and Technologies, Lilly, S.A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Alma Jiménez
- Discovery Chemistry Research and Technologies, Lilly, S.A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Ana I Mateo
- Discovery Chemistry Research and Technologies, Lilly, S.A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Ana M Castaño
- Discovery Chemistry Research and Technologies, Lilly, S.A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Daniel A Briere
- Diabetes and Complications, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - Kyle W Sloop
- Diabetes and Complications, Lilly Research Laboratories, Indianapolis, Indiana 46285, United States
| | - Ana B Bueno
- Discovery Chemistry Research and Technologies, Lilly, S.A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| |
Collapse
|
2
|
Bueno AB, Sun B, Willard FS, Feng D, Ho JD, Wainscott DB, Showalter AD, Vieth M, Chen Q, Stutsman C, Chau B, Ficorilli J, Agejas FJ, Cumming GR, Jiménez A, Rojo I, Kobilka TS, Kobilka BK, Sloop KW. Structural insights into probe-dependent positive allosterism of the GLP-1 receptor. Nat Chem Biol 2020. [PMID: 32690941 DOI: 10.1038/s41589‐020‐0589‐7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Drugs that promote the association of protein complexes are an emerging therapeutic strategy. We report discovery of a G protein-coupled receptor (GPCR) ligand that stabilizes an active state conformation by cooperatively binding both the receptor and orthosteric ligand, thereby acting as a 'molecular glue'. LSN3160440 is a positive allosteric modulator of the GLP-1R optimized to increase the affinity and efficacy of GLP-1(9-36), a proteolytic product of GLP-1(7-36). The compound enhances insulin secretion in a glucose-, ligand- and GLP-1R-dependent manner. Cryo-electron microscopy determined the structure of the GLP-1R bound to LSN3160440 in complex with GLP-1 and heterotrimeric Gs. The modulator binds high in the helical bundle at an interface between TM1 and TM2, allowing access to the peptide ligand. Pharmacological characterization showed strong probe dependence of LSN3160440 for GLP-1(9-36) versus oxyntomodulin that is driven by a single residue. Our findings expand protein-protein modulation drug discovery to uncompetitive, active state stabilizers for peptide hormone receptors.
Collapse
Affiliation(s)
| | | | - Francis S Willard
- Quantitative Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Dan Feng
- ConfometRx, Santa Clara, CA, USA
| | - Joseph D Ho
- Lilly Biotechnology Center San Diego, San Diego, CA, USA
| | - David B Wainscott
- Quantitative Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Aaron D Showalter
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Michal Vieth
- Lilly Biotechnology Center San Diego, San Diego, CA, USA
| | - Qi Chen
- Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Cynthia Stutsman
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Betty Chau
- Lilly Biotechnology Center San Diego, San Diego, CA, USA
| | - James Ficorilli
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | | | | | | | | | | | | | - Kyle W Sloop
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
| |
Collapse
|
3
|
Bueno AB, Sun B, Willard FS, Feng D, Ho JD, Wainscott DB, Showalter AD, Vieth M, Chen Q, Stutsman C, Chau B, Ficorilli J, Agejas FJ, Cumming GR, Jiménez A, Rojo I, Kobilka TS, Kobilka BK, Sloop KW. Structural insights into probe-dependent positive allosterism of the GLP-1 receptor. Nat Chem Biol 2020; 16:1105-1110. [PMID: 32690941 DOI: 10.1038/s41589-020-0589-7] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Accepted: 06/09/2020] [Indexed: 12/19/2022]
Abstract
Drugs that promote the association of protein complexes are an emerging therapeutic strategy. We report discovery of a G protein-coupled receptor (GPCR) ligand that stabilizes an active state conformation by cooperatively binding both the receptor and orthosteric ligand, thereby acting as a 'molecular glue'. LSN3160440 is a positive allosteric modulator of the GLP-1R optimized to increase the affinity and efficacy of GLP-1(9-36), a proteolytic product of GLP-1(7-36). The compound enhances insulin secretion in a glucose-, ligand- and GLP-1R-dependent manner. Cryo-electron microscopy determined the structure of the GLP-1R bound to LSN3160440 in complex with GLP-1 and heterotrimeric Gs. The modulator binds high in the helical bundle at an interface between TM1 and TM2, allowing access to the peptide ligand. Pharmacological characterization showed strong probe dependence of LSN3160440 for GLP-1(9-36) versus oxyntomodulin that is driven by a single residue. Our findings expand protein-protein modulation drug discovery to uncompetitive, active state stabilizers for peptide hormone receptors.
Collapse
Affiliation(s)
| | | | - Francis S Willard
- Quantitative Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Dan Feng
- ConfometRx, Santa Clara, CA, USA
| | - Joseph D Ho
- Lilly Biotechnology Center San Diego, San Diego, CA, USA
| | - David B Wainscott
- Quantitative Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Aaron D Showalter
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Michal Vieth
- Lilly Biotechnology Center San Diego, San Diego, CA, USA
| | - Qi Chen
- Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Cynthia Stutsman
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Betty Chau
- Lilly Biotechnology Center San Diego, San Diego, CA, USA
| | - James Ficorilli
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | | | | | | | | | | | | | - Kyle W Sloop
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
| |
Collapse
|
4
|
Briere DA, Bueno AB, Gunn EJ, Michael MD, Sloop KW. Mechanisms to Elevate Endogenous GLP-1 Beyond Injectable GLP-1 Analogs and Metabolic Surgery. Diabetes 2018; 67:309-320. [PMID: 29203510 DOI: 10.2337/db17-0607] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2017] [Accepted: 11/16/2017] [Indexed: 11/13/2022]
Abstract
Therapeutic engineering of glucagon-like peptide 1 (GLP-1) has enabled development of new medicines to treat type 2 diabetes. These injectable analogs achieve robust glycemic control by increasing concentrations of "GLP-1 equivalents" (∼50 pmol/L). Similar levels of endogenous GLP-1 occur after gastric bypass surgery, and mechanistic studies indicate glucose lowering by these procedures is driven by GLP-1. Therefore, because of the remarkable signaling and secretory capacity of the GLP-1 system, we sought to discover mechanisms that increase GLP-1 pharmacologically. To study active GLP-1, glucose-dependent insulinotropic polypeptide receptor (Gipr)-deficient mice receiving background dipeptidyl peptidase 4 (DPP4) inhibitor treatment were characterized as a model for evaluating oral agents that increase circulating GLP-1. A somatostatin receptor 5 antagonist, which blunts inhibition of GLP-1 release, and agonists for TGR5 and GPR40, which stimulate GLP-1 secretion, were investigated alone and in combination with the DPP4 inhibitor sitagliptin; these only modestly increased GLP-1 (∼5-30 pmol/L). However, combining molecules to simultaneously intervene at multiple regulatory nodes synergistically elevated active GLP-1 to unprecedented concentrations (∼300-400 pmol/L), drastically reducing glucose in Gipr null and Leprdb/db mice in a GLP-1 receptor-dependent manner. Our studies demonstrate that complementary pathways can be engaged to robustly increase GLP-1 without invasive surgical or injection regimens.
Collapse
MESH Headings
- Administration, Oral
- Animals
- Diabetes Mellitus, Type 2/blood
- Diabetes Mellitus, Type 2/drug therapy
- Diabetes Mellitus, Type 2/metabolism
- Dipeptidyl-Peptidase IV Inhibitors/administration & dosage
- Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
- Drug Design
- Drug Evaluation, Preclinical
- Drug Resistance
- Drug Synergism
- Drug Therapy, Combination
- Drugs, Investigational/administration & dosage
- Drugs, Investigational/therapeutic use
- Glucagon-Like Peptide 1/administration & dosage
- Glucagon-Like Peptide 1/analogs & derivatives
- Glucagon-Like Peptide 1/blood
- Glucagon-Like Peptide 1/therapeutic use
- Hyperglycemia/prevention & control
- Male
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, Mutant Strains
- Models, Biological
- Proof of Concept Study
- Receptors, G-Protein-Coupled/agonists
- Receptors, G-Protein-Coupled/metabolism
- Receptors, Gastrointestinal Hormone/genetics
- Receptors, Gastrointestinal Hormone/metabolism
- Sitagliptin Phosphate/therapeutic use
Collapse
Affiliation(s)
- Daniel A Briere
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
| | - Ana B Bueno
- Centro de Investigación Lilly, Eli Lilly and Company, Alcobendas, Spain
| | | | - M Dodson Michael
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
| | - Kyle W Sloop
- Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
| |
Collapse
|
5
|
Bueno AB, Agejas J, Broughton H, Dally R, Durham TB, Espinosa JF, González R, Hahn PJ, Marcos A, Rodríguez R, Sanz G, Soriano JF, Timm D, Vidal P, Yang HC, McCarthy JR. Optimization of Hydroxyethylamine Transition State Isosteres as Aspartic Protease Inhibitors by Exploiting Conformational Preferences. J Med Chem 2017; 60:9807-9820. [PMID: 29088532 DOI: 10.1021/acs.jmedchem.7b01304] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
NMR conformational analysis of a hydroxyethylamine peptide isostere developed as an aspartic protease inhibitor shows that it is a flexible architecture. Cyclization to form pyrrolidines, piperidines, or morpholines results in a preorganization of the whole system in solution. The resulting conformation is similar to the conformation of the inhibitor in the active site of BACE-1. This entropic gain results in increased affinity for the enzyme when compared with the acyclic system. For morpholines 27 and 29, the combination of steric and electronic factors is exploited to orient substituents toward S1, S1', and S2' pockets both in the solution and in the bound states. These highly preorganized molecules proved to be the most potent compounds of the series. Additionally, the morpholines, unlike the pyrrolidine and piperidine analogues, have been found to be brain penetrant BACE-1 inhibitors.
Collapse
Affiliation(s)
- Ana B Bueno
- Lilly SA , Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain
| | - Javier Agejas
- Lilly SA , Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain
| | - Howard Broughton
- Lilly SA , Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain
| | - Robert Dally
- Lilly Research Laboratories , Indianapolis, Indiana 46285, United States
| | - Timothy B Durham
- Lilly Research Laboratories , Indianapolis, Indiana 46285, United States
| | | | - Rosario González
- Lilly SA , Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain
| | - Patric J Hahn
- Lilly Research Laboratories , Indianapolis, Indiana 46285, United States
| | - Alicia Marcos
- Lilly SA , Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain
| | - Ramón Rodríguez
- Lilly SA , Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain
| | - Gema Sanz
- Lilly SA , Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain
| | - José F Soriano
- Lilly SA , Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain
| | - David Timm
- Lilly Research Laboratories , Indianapolis, Indiana 46285, United States
| | - Paloma Vidal
- Lilly SA , Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain
| | - Hsiu-Chiung Yang
- Lilly Research Laboratories , Indianapolis, Indiana 46285, United States
| | - James R McCarthy
- Lilly Research Laboratories , Indianapolis, Indiana 46285, United States
| |
Collapse
|
6
|
Bueno AB, Showalter AD, Wainscott DB, Stutsman C, Marín A, Ficorilli J, Cabrera O, Willard FS, Sloop KW. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles. J Biol Chem 2016; 291:10700-15. [PMID: 26975372 PMCID: PMC4865917 DOI: 10.1074/jbc.m115.696039] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Indexed: 11/25/2022] Open
Abstract
Therapeutic intervention to activate the glucagon-like peptide-1 receptor (GLP-1R) enhances glucose-dependent insulin secretion and improves energy balance in patients with type 2 diabetes mellitus. Studies investigating mechanisms whereby peptide ligands activate GLP-1R have utilized mutagenesis, receptor chimeras, photo-affinity labeling, hydrogen-deuterium exchange, and crystallography of the ligand-binding ectodomain to establish receptor homology models. However, this has not enabled the design or discovery of drug-like non-peptide GLP-1R activators. Recently, studies investigating 4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine (BETP), a GLP-1R-positive allosteric modulator, determined that Cys-347 in the GLP-1R is required for positive allosteric modulator activity via covalent modification. To advance small molecule activation of the GLP-1R, we characterized the insulinotropic mechanism of BETP. In guanosine 5′-3-O-(thio)triphosphate binding and INS1 832-3 insulinoma cell cAMP assays, BETP enhanced GLP-1(9–36)-NH2-stimulated cAMP signaling. Using isolated pancreatic islets, BETP potentiated insulin secretion in a glucose-dependent manner that requires both the peptide ligand and GLP-1R. In studies of the covalent mechanism, PAGE fluorography showed labeling of GLP-1R in immunoprecipitation experiments from GLP-1R-expressing cells incubated with [3H]BETP. Furthermore, we investigated whether other reported GLP-1R activators and compounds identified from screening campaigns modulate GLP-1R by covalent modification. Similar to BETP, several molecules were found to enhance GLP-1R signaling in a Cys-347-dependent manner. These chemotypes are electrophiles that react with GSH, and LC/MS determined the cysteine adducts formed upon conjugation. Together, our results suggest covalent modification may be used to stabilize the GLP-1R in an active conformation. Moreover, the findings provide pharmacological guidance for the discovery and characterization of small molecule GLP-1R ligands as possible therapeutics.
Collapse
Affiliation(s)
- Ana B Bueno
- From the Centro de Investigación Lilly, Eli Lilly and Co., Alcobendas 28108, Spain and
| | | | - David B Wainscott
- Quantitative Biology, Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285
| | | | - Aranzazu Marín
- From the Centro de Investigación Lilly, Eli Lilly and Co., Alcobendas 28108, Spain and
| | | | | | - Francis S Willard
- Quantitative Biology, Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285
| | | |
Collapse
|
7
|
Genin MJ, Bueno AB, Agejas Francisco J, Manninen PR, Bocchinfuso WP, Montrose-Rafizadeh C, Cannady EA, Jones TM, Stille JR, Raddad E, Reidy C, Cox A, Michael MD, Michael LF. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia. J Med Chem 2015; 58:9768-72. [PMID: 26568144 DOI: 10.1021/acs.jmedchem.5b01161] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The farnesoid X receptor (FXR) is a member of the "metabolic" subfamily of nuclear receptors. Several FXR agonists have been reported in the literature to have profound effects on plasma lipids in animal models. To discover novel and effective therapies for dyslipidemia and atherosclerosis, we have developed a series of potent FXR agonists that robustly lower plasma LDL and vLDL in LDLr-/- mice. To this end the novel piperidinylisoxazole system LY2562175 was discovered. This molecule is a potent and selective FXR agonist in vitro and has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species. The preclinical ADME properties of LY2562175 were consistent with enabling once daily dosing in humans, and it was ultimately advanced to the clinic for evaluation in humans. The synthesis and biological profile of this molecule is discussed.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - John R Stille
- Chorus, Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Eyas Raddad
- Chorus, Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | | | | | | | | |
Collapse
|
8
|
Wootten D, Savage EE, Willard FS, Bueno AB, Sloop KW, Christopoulos A, Sexton PM. Differential Activation and Modulation of the Glucagon-Like Peptide-1 Receptor by Small Molecule Ligands. Mol Pharmacol 2013; 83:822-34. [DOI: 10.1124/mol.112.084525] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
9
|
Bueno AB, Gilmore J, Boot J, Broadmore R, Cooper J, Findlay J, Hayhurst L, Marcos A, Montero C, Mitchell S, Timms G, Tomlinson R, Wallace L, Walton L. Naphthyl piperazines with dual activity as 5-HT1D antagonists and 5-HT reuptake inhibitors. Bioorg Med Chem Lett 2007; 17:3344-8. [PMID: 17434731 DOI: 10.1016/j.bmcl.2007.03.101] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2007] [Revised: 03/28/2007] [Accepted: 03/30/2007] [Indexed: 11/16/2022]
Abstract
SAR around a known molecule with dual 5-HT(1D) antagonist and 5-HT(transporter) inhibitory activity has led to the discovery of molecules with improved dual activity and reduced cross-reactivity toward other aminergic receptors (5-HT(1B), alpha(1), and D(2)).
Collapse
Affiliation(s)
- Ana B Bueno
- Lilly SA, Avda. de la Industria, 30, 28108, Alcobendas, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
|
11
|
Bueno AB, Flynn CJ, Gilmore J, Marcos A, Montero C, Porter W, Williams AC. A versatile protocol for the preparation of substituted 1- and 2-naphthyl piperazines from aminonaphthols. Tetrahedron Lett 2005. [DOI: 10.1016/j.tetlet.2005.09.052] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Pérez-Barrero P, Gil L, Martínez C, Bueno AB, Casado AI, Oro J. [Treatment with desmopressin before epidural anesthesia in a patient with type I von Willebrand disease]. Rev Esp Anestesiol Reanim 2003; 50:526-9. [PMID: 14737779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
Abstract
A 33-year-old primipara with von Willebrand disease type I was admitted in labor at 37 weeks, requesting epidural analgesia. The consultant hematologist advised treating with desmopressin acetate (DDAVP) before inserting an epidural catheter. Desmopressin at a dose of 0.3 microgram/Kg was administered intravenously and the catheter was inserted to L3-L4 to infuse 0.1% bupivacaine with 2 micrograms/mL of fentanyl at a rate of 12 mL/h. Four hours later the patient was brought to the operating room for forceps delivery of a healthy boy. One hour later, she had recovered normal motor tone followed by normal sensitivity in the lower extremities. The catheter was then withdrawn with no signs of bleeding. A woman with von Willebrand's disease can receive an epidural block for analgesia during childbirth. The decision to perform the block should be individualized, based on coagulation tests. DDAVP may play a role in improving hemostasis.
Collapse
Affiliation(s)
- P Pérez-Barrero
- Servicio de Anestesia, Reanimación y Terapia del Dolor Hospital Universitario Miguel Servet Paseo Isabel La Católica, 1-3 50009 Zaragoza.
| | | | | | | | | | | |
Collapse
|
13
|
Pascual Bellosta A, Martínez Ubieto J, Ortega Lucea S, Muñoz Rodríguez L, Lafuente F, Bueno AB, Pardillos Calatayud C. [The use of laryngeal mask in a female patient with sclerodermia]. Rev Esp Anestesiol Reanim 2002; 49:57-8. [PMID: 11898454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
|
14
|
Affiliation(s)
- Ana B. Bueno
- Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523
| | - William H. Moser
- Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523
| | - Louis S. Hegedus
- Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523
| |
Collapse
|
15
|
Bueno AB, Hegedus LS. Synthesis and Reactivity of Optically Active Spiroketals by Ring-Expansion of Chromium Carbene Complex-Derived Cyclobutanones. J Org Chem 1998; 63:684-690. [PMID: 11672061 DOI: 10.1021/jo971665v] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Photolysis of cyclic chromium alkoxycarbene complexes with an optically active ene-carbamate gave spirofused, optically active cyclobutanones. Baeyer-Villiger ring expansion followed by further functionalization gave optically active spiroketals. Photochemical ring expansion of these spirofused cyclobutanones in the presence of acetic acid or thiophenol gave 2-acetoxy- or 2-(thiophenoxy)-4-spirofused tetrahydrofurans. Elimination of the thiophenoxy group gave a 3,4-dihydrofuran that underwent Heck arylation and photochemical cycloaddition with chromium carbene complexes to give cyclobutanones.
Collapse
Affiliation(s)
- Ana B. Bueno
- Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523
| | | |
Collapse
|
16
|
Bueno AB, Carreño MC, García Ruano JL, Arrayás RG, Zarzuelo MM. Sulfoxide-Mediated Asymmetric Synthesis of Glycosidase Inhibitor Precursors. J Org Chem 1997; 62:2139-2143. [PMID: 11671519 DOI: 10.1021/jo961774u] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The highly diastereoselective DIBALH and DIBALH/ZnBr(2) reduction of enantiomerically pure (5S,(S)S)-3-ethoxy-5-(p-tolylsulfinyl)cyclopentenone (9) is used as a key step to the synthesis of oxazolidinone 2, a precursor of glycosidase inhibitor mannostatin. Compound 9 was obtained from 3-ethoxycyclopentenone by direct sulfinylation with (S)-N-benzyl-N-(p-tolylsulfinyl)propionamide.
Collapse
Affiliation(s)
- Ana B. Bueno
- Departamento de Química Orgánica (C-I), Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
| | | | | | | | | |
Collapse
|
17
|
|
18
|
Bueno AB, Carreño M, Garcia Ruano JL. Stereochemistry of Nueleophilic Epoxidation of (S)-2-p-tolylsulfonyl-2-cyclohexenol and O-derivatives. Tetrahedron Lett 1993. [DOI: 10.1016/s0040-4039(00)74070-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Carreño M, García Ruano JL, Maestro M, González MP, Bueno AB, Fischer J. Stereoselective reactions of AlMe3 with chiral acyclic β-ketosulfoxides. Tetrahedron 1993. [DOI: 10.1016/s0040-4020(01)80254-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Bueno AB, Carmen Carreño M, Fischer J, García Ruano J, Peña B, Peñas L, Rubio A. Reactions of chiral 2-p-tolylsulfinycycloalkanones with AlMe3. Tetrahedron Lett 1991. [DOI: 10.1016/s0040-4039(00)79719-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|